©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2015; 21(15): 4744-4749
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4744
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4744
Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis
Wen-Song Ge, Jian-Gao Fan, Department of Gastroenterology, Shanghai Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Author contributions: Fan JG designed the study; Ge WS and Fan JG screened the citations, performed the data analysis and wrote the paper.
Supported by National Natural Science Foundation of China, No. 81200279; and Medical-Engineering (Science) cross-Research Fund of Shanghai Jiao Tong University, No. YG2011MS29.
Correspondence to: Jian-Gao Fan, MD, Department of Gastroenterology, Shanghai Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai 200092, China. xinhuafjg@126.com
Telephone: +86-21-25077344 Fax: +86-21-25077345
Received: September 2, 2014
Peer-review started: September 3, 2014
First decision: September 27, 2014
Revised: October 11, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: April 21, 2015
Processing time: 229 Days and 22 Hours
Peer-review started: September 3, 2014
First decision: September 27, 2014
Revised: October 11, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: April 21, 2015
Processing time: 229 Days and 22 Hours
Core Tip
Core tip: Integrin antagonists were used to treat Crohn’s disease (CD), but their efficacy and safety are not yet certain. We performed this systematic review and meta-analysis to evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in CD. During 6-12 wk treatment, integrin antagonists increased the rate of clinical response and remission. There was no significant difference between integrin antagonists and placebo regarding their adverse reactions and serious adverse reactions. These results prove the efficacy and safety of integrin antagonists for CD treatment.